Please login to the form below

Not currently logged in
Email:
Password:

Nanobiotix strengthens US leadership team

Dr Mihail Obrocea and Noël Kurdi join the nanomedicine company

Nanobiotix Dr Mihail ObroceaFrench oncology specialist Nanobiotix has strengthened its US leadership team with the appointments of Dr Mihail Obrocea and Noël Kurdi.

Dr Obrocea (pictured right) joins Nanobiotix as head of US clinical development, bringing 20 years of clinical research leadership to the role.

Most recently, Dr Obrocea was AbbVie Biotherapeutics' project director and oncology clinical lead, overseeing a number of trials in oncology and hematology.

He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

Nanobiotix Noel KurdiMeanwhile, Kurdi (pictured left) becomes director of investor relations at Nanobiotix, moving from the Trout Group where she served as a senior associate.

Kurdi has previously worked in institutional equity sales and research at Brean Capital, and business development and investor relations at AIG Investments in New York.

7th October 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics